[
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03931551",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Triple-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Olaparib",
        "Description":"In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib.",
        "rs value":null,
        "pmid":"PubMed:21862407",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Loss-of-function",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":"In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg\/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.",
        "rs value":null,
        "pmid":"PubMed:28242752",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Loss-of-function",
        "Disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had significantly improved progression-free survival and better response rate to olaparib (PARP inhibitor) than standard therapy (7.0 mo vs 4.2 mo, hazard ratio 0.58, 95% CI 0.43-0.8) in this randomized phase 3 trial (NCT02000622). For BRCA1 patients specifically, the hazard ratio was 0.54, 95% CI 0.37-0.79).",
        "rs value":null,
        "pmid":"PubMed:28578601",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2\ufffd\ufffd\ufffdnegative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy ",
        "rs value":null,
        "pmid":"PubMed:28792849",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Loss-of-function",
        "Disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER\/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo.  Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86).",
        "rs value":null,
        "pmid":"PubMed:34081848",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Loss-of-function",
        "Disease":"Triple-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER\/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo. Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86).",
        "rs value":null,
        "pmid":"PubMed:34081848",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Onalespib lactate + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02627430",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00679783",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01630226",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01149083",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00664781",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02034916",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Denosumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04711109",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02000622",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT01945775",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02032823",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin hydrochloride liposome + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01145430",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02264678",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02208375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Vistusertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02208375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02561832",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03329937",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01351909",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Veliparib + Vinorelbine",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01104259",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01251874",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04499118",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05519670",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TSL-1502",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05420779",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lurbinectedin",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02454972",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + Epirubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04499118",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01074970",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dexamethasone + Trabectedin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00580112",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Durvalumab + Olaparib + Stereotactic radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04711824",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Mercaptopurine + Methotrexate",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01432145",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Docetaxel + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04664972",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"M4344 + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04655183",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03330405",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Famitinb + Fluzoparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03805399",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SC10914",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04556292",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Aromatase inhibitors + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04240106",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Prophylactic contralateral breast irradiation",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04960839",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dalpiciclib + Fluzoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04355858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Docetaxel + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04499118",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pamiparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03575065",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05033756",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03025035",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cediranib maleate + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04090567",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Sapacitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03641755",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Adavosertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03330847",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ceralasertib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03330847",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05629429",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05209529",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02484404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03990896",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02826512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01009788",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01506609",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01306032",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02595905",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01506609",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02505048",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04755868",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_Mutation",
        "Disease":"Triple-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin,Carboplatin",
        "Description":"In an evaluation of 77 patients, those who had BRCA1\/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different.",
        "rs value":null,
        "pmid":"PubMed:25847936",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05498155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03499353",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02282345",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05498155",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02681562",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01661868",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02849496",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03286842",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Fluzoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04296370",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03150576",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04915755",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01905592",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Fulvestrant + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04053322",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Chemotherapy + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03598270",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Cyclophosphamide + Paclitaxel + Veliparib + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02032277",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02163694",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04330040",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Choriogonadotropin alfa",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03495609",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Buparlisib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01623349",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01623349",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05485766",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_CHEK2_unspecified_or_PALB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HX008 + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04508803",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05332561",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03598270",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD9574",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05417594",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT2",
        "Genomic Position":"19:40736224-40791302(-) | 19q13.2",
        "CDS Mutation":null,
        "AA Mutation":"AKT2_EXPRESSION",
        "Disease":"Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trastuzumab",
        "Description":"In HER2+ metastatic breast cancer treated with trastuzumab (n = 74 patients), the expression of AKT2 and pAkt-Thr308 and\/or pAkt-Ser473 localized in nucleus+cytoplasm was associated with an improved time to progression (TTP) and overall survival (OS) compared to AKT2 negative tumors as measured by immunohistochemistry.",
        "rs value":null,
        "pmid":"PubMed:22842582",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":"c.2606T>G",
        "AA Mutation":"p.L869R",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31867841",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RB1",
        "Genomic Position":"13:48877911-49056122(+) | 13q14.2",
        "CDS Mutation":null,
        "AA Mutation":"RB1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01320592",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RB1",
        "Genomic Position":"13:48877911-49056122(+) | 13q14.2",
        "CDS Mutation":null,
        "AA Mutation":"RB1_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04360941",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RB1",
        "Genomic Position":"13:48877911-49056122(+) | 13q14.2",
        "CDS Mutation":null,
        "AA Mutation":"RB1_PHOSPHORYLATION",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Alpelisib",
        "Description":"The p110alpha-specific PI3K inhibitor BYL719 (Alpelisib) was used on a panel of five PI3K inhibitor sensitive and five resistant breast cancer cell lines. Sensitive cells (IC50<400nM) showed reduced phospho-Rb (p-Rb) western blot levels in response to BYL719 treatment, while resistant cell lines (IC50>800nM) showed significantly less reduction in p-Rb after BYL719. Paired biopsies before and after treatment were taken from a set of eight patients classified as either responder or non-responder to BYL719. Responder samples showed significantly reduced p-Rb staining after treatment in comparison to non-responder biopsies. In biopsies taken from a group of three responders who progressed, p-Rb levels were increased after progression.",
        "rs value":null,
        "pmid":"PubMed:25002028",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RB1",
        "Genomic Position":"13:48877911-49056122(+) | 13q14.2",
        "CDS Mutation":null,
        "AA Mutation":"RB1_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03130439",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NF2",
        "Genomic Position":"22:29999547-30094587(+) | 22q12.2",
        "CDS Mutation":null,
        "AA Mutation":"NF2_K159fs",
        "Disease":"Breast Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temsirolimus",
        "Description":"23 patients were treated with temsirolimus containing regimens. 1 patient with a complete response >3 years had a K159fs*16 mutation in NF2. 2 patients were tested for NF2 mutations.",
        "rs value":null,
        "pmid":"PubMed:25878190",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"IGF1R",
        "Genomic Position":"15:99192200-99507759(+) | 15q26.3",
        "CDS Mutation":null,
        "AA Mutation":"IGF1R_Overexpression",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Exemestane,Metformin",
        "Description":"A randomized phase III trial of hormone sensitive (ER or PR positive) early stage breast cancer (Dutch TEAM cohort, n=2,446) examined the addition of metformin to exemestane for 155 patients. IGF1R IHC was performed and patients classified as IGF1R high (n=105) or low (n=50). In IGF1R-high patients, combining metformin with exemestane was associated with significant RFS (HR 1.12, 95% CI 0.57\ufffd\ufffd\ufffd2.23 for sequential treatment with metformin, HR 0.73 95% CI 0.56\ufffd\ufffd\ufffd0.94 for exemestane only, and HR 0.32, 95% CI 0.10\ufffd\ufffd\ufffd1.00 for exemestane with metformin, p = 0.02, compared to the sequential treatment arm). There was also significant association with OS (HR for OS 1.72, 95% CI 0.96\ufffd\ufffd\ufffd3.08 for sequential treatment with metformin, HR 0.80, 95% CI 0.62\ufffd\ufffd\ufffd1.03 for exemestane only, and HR 0.67, 95% CI 0.31\ufffd\ufffd\ufffd1.45 for exemestane with metformin, p = 0.03, compared to the sequential treatment arm). The authors conclude that adding metformin to exemestane for patients with IGF1R-high e",
        "rs value":null,
        "pmid":"PubMed:26706833",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TUBB3",
        "Genomic Position":"16:89989687-90002505(+) | 16q24.3",
        "CDS Mutation":null,
        "AA Mutation":"TUBB3_EXPRESSION",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Taxane Compound",
        "Description":"High expression of betaIII-tubulin, as assessed in 85 breast cancers by IHC, was associated with better pathological response.",
        "rs value":null,
        "pmid":"PubMed:23218766",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | HER-positive carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02774681",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_CDKN2A_unspecified_or_CDK4_unspecified_or_CDK6_unspecified)_and_ESR1_unspecified",
        "Disease":"breast | carcinoma | ER-positive carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Letrozole + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01740427",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_or_ESR1_unspecified_or_PGR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Letrozole + Palbociclib + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05429684",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_Overexpression",
        "Disease":"Estrogen-receptor Positive Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tamoxifen",
        "Description":"The authors performed a tissue microarray analysis of 167 postmenopausal breast cancers that had been randomized to treatment with or without tamoxifen.  ER +ve patients with high CCND1 tumor expression did not show any difference in survival between tamoxifen and no treatment.",
        "rs value":null,
        "pmid":"PubMed:15138475",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | HER-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Inetetamab + Pyrotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04681911",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_and_ESR1_unspecified",
        "Disease":"breast | carcinoma | ER-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02936206",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCND1",
        "Genomic Position":"11:69455855-69469242(+) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"CCND1_unspecified_and_ESR1_unspecified",
        "Disease":"breast | carcinoma | ER-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Zotatifin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04092673",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FOXP3",
        "Genomic Position":"X:49106897-49121288(-) | Xp11.23",
        "CDS Mutation":null,
        "AA Mutation":"FOXP3_EXPRESSION",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Epirubicin",
        "Description":"1,097 patients with breast cancer were evaluated for FOXP3 expression by IHC. FOXP3 expression was found in 405 tumor samples and associated with improved OS in patients treated with anthracycline-based adjuvant chemotherapy (6 cycles of 'FEC100' aka epirubicin + cyclophosphamide + 5-fluorouracil) but not in patients treated with sequential anthracycline->taxane (3 cycles of FEC100 followed by 3 cycles of docetaxel). In-vitro experiments confirmed that FOXP3 expression enhance anthracycline efficacy. The in vitro data consisted of testing the sensitivity of various breast cancer cell lines to anthracyclines after treatment with valproic acid (which increases FOXP3 expression). The authors observed that, while valproic acid has no intrinsic cytotoxic effect on tumor cells, it enhanced the cytotoxic effect of epirubicin specifically in cell lines where FOXP3 expression was increased.",
        "rs value":null,
        "pmid":"PubMed:22431701",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TFF3",
        "Genomic Position":"21:43731777-43735761(-) | 21q22.3",
        "CDS Mutation":null,
        "AA Mutation":"TFF3_EXPRESSION",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Aminoglutethimide,Tamoxifen",
        "Description":"TFF3 expression was assessed by IHC in 75 patients, 187 patients were identified for the validation cohort. TFF3 expression was associated with response to endocrine therapy (tamoxifen, aminoglutethimide or oophorectomy) and outperformed ER, PR and TFF1 as biomarkers.",
        "rs value":null,
        "pmid":"PubMed:25900183",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BIRC5",
        "Genomic Position":"17:76210267-76221717(+) | 17q25.3",
        "CDS Mutation":null,
        "AA Mutation":"BIRC5_Overexpression",
        "Disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Trastuzumab",
        "Description":"13 HER2 breast cancer patients were treated with trastuzumab and then trastuzumab + docetaxel prior to surgery. Pretreatment biopsies and post-treatment surgical samples were obtained, and microarray performed. 5 of 13 patients responded to treatment, and pretreatment biopsies from non-responders showed significantly higher survivin (BIRC5) mRNA (p=0.026) levels than responders. In HER2 positive, trastuzumab-sensitive BT474 cells, overexpression of survivin blunted sensitivity to trastuzumab. In HER2 positive trastuzumab-resistant breast cancer cell lines, knockdown of survivin with RNAi or with YM155 induced growth inhibition and apoptosis.",
        "rs value":null,
        "pmid":"PubMed:23204226",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"FGFR1",
        "Genomic Position":"8:38268656-38325363(-) | 8p11.23",
        "CDS Mutation":"c.1731C>A",
        "AA Mutation":"p.N577K",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30914635",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGF3",
        "Genomic Position":"11:69624992-69633792(-) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"FGF3_Amplification",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dovitinib",
        "Description":"81 patients were enrolled in a clinical trial with the FGFR inhibitor dovitinib. Four of these patients had FGF3 amplifications (qPCR) and showed tumor reductions of 100%, 30.8%, 23.0%, and 7.5%, respectively. 3 of these 4 patients also had FGFR1 amplifications (\ufffd\ufffd\ufffd6 copies by qPCR) and the fourth presented with FGFR1-gene gain (3.4 copies of FGFR1 by qPCR and SISH nega",
        "rs value":null,
        "pmid":"PubMed:23658459",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_deletion_and_PDCD4_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pemrametostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04676516",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDKN2A",
        "Genomic Position":"9:21968055-21974865(-) | 9p21.3",
        "CDS Mutation":null,
        "AA Mutation":"CDKN2A_Loss",
        "Disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Letrozole,Palbociclib",
        "Description":"A patient with metastatic ER-positive, her2-negative breast cancer with CDKN2A loss experienced a short-lived (~3-month) clinical response to palbociclib when given in combination with letrozole.",
        "rs value":null,
        "pmid":"PubMed:26715889",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TIMP1",
        "Genomic Position":"X:47441712-47446188(+) | Xp11.3",
        "CDS Mutation":null,
        "AA Mutation":"TIMP1_Overexpression",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Paclitaxel",
        "Description":"High expression of TIMP-1 was assessed by IHC in 99 primary breast cancers that had not spread beyond the breast after 6 postoperative courses of paclitaxel-based chemotherapy. High TIMP1 levels were associated with worse 5-year disease free survival (71.1%) than low levels (88.5 %; P = 0.020). High TIMP-1 levels were also associated with worse 5-year overall survival (78.9 %) than low levels (96.7 %; P = 0.004).",
        "rs value":null,
        "pmid":"PubMed:22544540",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_Mutation",
        "Disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Trastuzumab",
        "Description":"The HER2 overexpressing breast cancer cell line BT-474 transduced with mutant PIK3CA H1047R demonstrated essentially normal proliferation under trastuzumab, while control cells showed negligible proliferation with trastuzumab. Sequencing of 55 HER2 breast cancer samples revealed 25% PIK3CA mutation rate and Kaplan Meier curves showed decreased time to progression for mutant PIK3CA at borderline statistical significance (p=0.052). This was potentially explained by presence of PTEN loss in wild-type PIK3CA sample and combining PTEN loss with PIK3CA mutation resulted in significant differences in time to progression (p=0.007).",
        "rs value":null,
        "pmid":"PubMed:17936563",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_Mutation",
        "Disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Lapatinib,Capecitabine",
        "Description":"In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors harbored PIK3CA mutations treated with standard of care capecitabine and lapatinib combination chemotherapy (n=39) were associated with lower median progression free survival (PFS), overall response rate (ORR), and overall survival (OS) compared to patients whose tumors harbored wild-type PIK3CA (n=87; PFS: 4.3 vs. 6.4 months, ORR: 17.1% vs 39.7%, OS 17.3 vs 27.8 mo).",
        "rs value":null,
        "pmid":"PubMed:26920887",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_Mutation",
        "Disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Trastuzumab",
        "Description":"In a retrospective study of 105 HER2-positive metastic breast cancer patients treated with trastuzumab-based therapy, the presence of a PIK3CA mutation (E542K, E545K, or H1047R) was associated with a greater risk of progression (HR = 2.50, P = 0.003, multivariate analysis) compared to wildtype PIK3CA.",
        "rs value":null,
        "pmid":"PubMed:21594665",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_H1047R",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib + Taselisib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02389842",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_Mutation",
        "Disease":"Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Trastuzumab",
        "Description":"In retrospective study of 175 metastatic breast cancer patients treated with trastuzumab-based therapy, the presence of a PIK3CA mutation (E542K, E545K, or H1047R) was associated with a greater risk of progression (HR = 1.86, P = 0.014, multivariate analysis ) compared to wildtype PIK3CA.",
        "rs value":null,
        "pmid":"PubMed:21594665",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib + Pictilisib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02389842",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Trastuzumab-emtansine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02038010",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Palbociclib + Taselisib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02389842",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified_or_PTEN_unspecified_or_TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus + Nab-paclitaxel + Trastuzumab + Trastuzumab-emtansine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05429684",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Epirubicin hydrochloride + Lapatinib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03273595",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04360941",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Pilaralisib + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01042925",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pilaralisib + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01042925",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Fulvestrant + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04862663",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00829166",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Ipatasertib + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04920708",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified)_and_(PIK3CA_Exon9_or_PIK3CA_Exon20)",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03386162",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Elacestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05563220",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Nab-paclitaxel + Tilarginine acetate",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05660083",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Enzalutamide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03207529",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Buparlisib + Letrozole",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01248494",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01226316",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Evexomostat",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05455619",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Buparlisib + Letrozole",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01923168",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_E545",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib,Fulvestrant",
        "Description":"In a phase 3 trial, 572 patients with hormone receptor positive, HER2 receptor negative advanced breast cancer who previously received endocrine therapy were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status (N=341). PIK3CA mutation was determined according to the presence or absence of any hot spot mutation in the C2, helical, and kinase domains of PI3K (corresponding to exon 7, 9, and 20, respectively). In the cohort of patients with PIK3CA-mutated cancer, PFS was 11 months in the alpelisib-fulvestrant group, as compared with 5.7 months in the placebo-fulvestrant group (HR 0.65, p<0.001). In the cohort without PIK3CA-mutated cancer, the HR was 0.85. Analyses of PFS according to mutation types showed consistent benefit of treatment with alpelisib\ufffd\ufffd\ufffdfulvestrant across prespecified subgroups, including E542K, E545X (N=105, HR 0.61, 95% CI 0.37-1), and H",
        "rs value":null,
        "pmid":"PubMed:31091374",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Canagliflozin + Serabelisib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04073680",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02379247",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_E542K",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant,Alpelisib",
        "Description":"In a phase 3 trial, 572 patients with hormone receptor positive, HER2 receptor negative advanced breast cancer who previously received endocrine therapy were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status (N=341). PIK3CA mutation was determined according to the presence or absence of any hot spot mutation in the C2, helical, and kinase domains of PI3K (corresponding to exon 7, 9, and 20, respectively). In the cohort of patients with PIK3CA-mutated cancer, PFS was 11 months in the alpelisib-fulvestrant group, as compared with 5.7 months in the placebo-fulvestrant group (HR 0.65, p<0.001). In the cohort without PIK3CA-mutated cancer, the HR was 0.85. Analyses of PFS according to mutation types showed consistent benefit of treatment with alpelisib\ufffd\ufffd\ufffdfulvestrant across prespecified subgroups, including E542K (N=60, HR 0.60, 95% CI 0.29-1.23), E545X, and H",
        "rs value":null,
        "pmid":"PubMed:31091374",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Copanlisib + Eribulin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04345913",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Capecitabine + Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03853707",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03853707",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03853707",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))_and_(PIK3CA_D1045N_or_PIK3CA_D1056N_or_PIK3CA_E103_G106delinsD_or_PIK3CA_E103_V105del_or_PIK3CA_E110del_or_PIK3CA_E365K_or_PIK3CA_E39K_or_PIK3CA_E418K_or_PIK3CA_E418K_or_PIK3CA_E453_L455del_or_PIK3CA_E453K_or_PIK3CA_E453Q_or_PIK3CA_E542Q_or_PIK3CA_E726K_or_PIK3CA_G1049R_or_PIK3CA_G106_E109del_or_PIK3CA_G106_R108del_or_PIK3CA_G106C_or_PIK3CA_G106V_or_PIK3CA_G106V_or_PIK3CA_G118D_or_PIK3CA_H1047I_or_PIK3CA_H450_P458del_or_PIK3CA_L452_G460del_or_PIK3CA_L455_G460delinsC_or_PIK3CA_M1004I_or_PIK3CA_M1043I_or_PIK3CA_M1043V_or_PIK3CA_N1044K_or_PIK3CA_N345K_or_PIK3CA_N345S_or_PIK3CA_P104_V105delinsL_or_PIK3CA_P539R_or_PIK3CA_Q546K_or_PIK3CA_Q546P_or_PIK3CA_Q75E_or_PIK3CA_R108H_or_PIK3CA_R38C_or_PIK3CA_R88Q_or_PIK3CA_R93W_or_PIK3CA_V105_G106del_or_PIK3CA_V105del_or_PIK3CA_Y1021H)",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Dapagliflozin + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05025735",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_H1047X",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant,Alpelisib",
        "Description":"In a phase 3 trial, patients with hormone receptor positive, HER2 receptor negative breast were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status.PIK3CA mutation was determined according to the presence or absence of any hot spot mutation in the C2, helical, and kinase domains of PI3K (corresponding to exon 7, 9, and 20, respectively). In the cohort of patients with PIK3CA-mutated cancer, PFS was 11 months in the alpelisib-fulvestrant group, as compared with 5.7 months in the placebo-fulvestrant group (HR 0.65, p<0.001). In the cohort without PIK3CA-mutated cancer, the HR was 0.85. Analyses of PFS according to mutation types showed consistent benefit of treatment with alpelisib\ufffd\ufffd\ufffdfulvestrant in across prespecified subgroups, including  E542K, E545X, and H",
        "rs value":null,
        "pmid":"PubMed:31091374",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Sapanisertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02412722",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03206203",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dactolisib + Letrozole",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01248494",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Inavolisib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05332561",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02423603",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02162719",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Letrozole",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01923168",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Ganitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01708161",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_Mutation",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant,Alpelisib",
        "Description":"In a phase 3 trial, patients with hormone receptor positive, HER2 receptor negative breast were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status. In the cohort of patients with PIK3CA-mutated cancer (defined by the presence of any PIK3CA mutation in mutation hot spots in the C2, helical, and kinase domains of PI3K corresponding to exons 7, 9, and 20, respectively), PFS was 11 months in the alpelisib-fulvestrant group, as compared with 5.7 months in the placebo-fulvestrant group (HR 0.65, 95% CI, 0.50 to 0.85, p<0.001). In the cohort without PIK3CA-mutated cancer, the HR was 0.85 (95% CI, 0.58 to 1.25). Overall response rate was also greater in the PIK3CA-mutant group (26.6% vs. 12.8%).",
        "rs value":null,
        "pmid":"PubMed:31091374",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_Mutation",
        "Disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":"Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger sequencing. In the BOLERO trials, patients with HER2-overexpressing advanced breast cancer were treated with trastuzumab, chemotherapy and randomized to receive either everolimus or placebo. In the pooled analysis of both trials, patients with PI3K mutations had longer progression-free survival with everolimus compared to placebo (HR 0.67 95%CI 0.45 to 1.00, P=0.05) whereas patients with PI3K wild type status did not benefit significantly (HR 1.1, 95%CI 0.83 to 1.46, P=0.5). The same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combinedly analyzed as hyperactive PI3K pathway. Patients with PI3K hyperactive pathway had a hazard ratio of 0.67 (95%CI 0.48 to 0.93, P=0.02) compared to HR 1.19 (95%CI 0.87 to 1.62, P=0.28) in patients with PI3K normal pathway. These trends were independently confirmed in both trials but only pooled results showed consistent statistical significance.",
        "rs value":null,
        "pmid":"PubMed:27091708",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Pictilisib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01740336",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Inavolisib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05646862",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK2206",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01319539",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel + Placebo",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04216472",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04305496",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04650581",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04251533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Placebo",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Buparlisib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01572727",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Gemcitabine + Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00894504",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Copanlisib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03803761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PIK3CA",
        "Genomic Position":"3:178866311-178957881(+) | 3q26.32",
        "CDS Mutation":null,
        "AA Mutation":"PIK3CA_H1047R",
        "Disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant,Everolimus",
        "Description":"Case report of a 44-year-old patient with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classical chemotherapeutic agents and anti-HER2 treatment. Thus, the combination of everolimus and fulvestrant was administered. The patient experienced stable disease and PFS of 10 months. Genetic testing of pleural effusion after disease progression revealed a PIK3CA H1047R gene mutation but was positive for PTEN expression (IHC).",
        "rs value":null,
        "pmid":"PubMed:27445490",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"SGK1",
        "Genomic Position":"6:134490384-134639196(-) | 6q23.2",
        "CDS Mutation":null,
        "AA Mutation":"SGK1_Overexpression",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Alpelisib",
        "Description":"A group of 18 breast cancer patients were treated with PI3Kalpha inhibitor alpelisib (NVP-BYL719) plus an aromatase inhbitor (NCT01870505). 3 out of 3 patients expressing high tumor SGK1 mRNA had disease progression as best response with median progression free survival (PFS) of 56 days, while 15 patients classified with low to medium SGK1 mRNA had median PFS 111 days with 4\/15 having disease progression as best response.",
        "rs value":null,
        "pmid":"PubMed:27451907",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_R249",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin",
        "Description":"Breast tumors with R175H or R249 mutations are more responsive to doxorubicin than breast tumors with wild type TP53.",
        "rs value":null,
        "pmid":"PubMed:9569050",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_DNA_Binding_Domain_Mutation",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tamoxifen",
        "Description":"In a study 202 breast cancer patients undergoing first line tamoxifen treatment, 65 patients had mutations in TP53. Among the p53 wild type population a 66% response rate was reported, where response was considered as complete response, partial response or stable disease. In a patient subgroup with mutations in p53 amino acids that directly interact with DNA, 2 of 11 (18%) of patients responded to tamoxifen.",
        "rs value":null,
        "pmid":"PubMed:10786679",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tamoxifen",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00004038",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"ALRN-6924 + Cyclophosphamide + Docetaxel + Doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05622058",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02965950",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene + Docetaxel + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00044993",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02645149",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Olaparib + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02624973",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_Mutation",
        "Disease":"Breast Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Tamoxifen",
        "Description":"In a study 202 breast cancer patients undergoing tamoxifen treatment, a higher frequency of wildtype TP53 patients responded to treatment compared to those with mutations in TP53 (66% wild-type vs. 31%, odds ratio (OR):0.22, 95CI:0.12-0.42, P<0.0001, univariate analysis; OR:0.29, 95% CI:0.12-0.42, P=0.0014, multivariate analysis). The median survival after start of therapy was shorter in patients with mutations in TP53 than for patients with wild-type TP53 (20mo vs. 29mo, HR:1.99,95% CI:1.43-2.75, P<0.001). Breast cancer patients with TP53 mutations also had a decrease in progression-free survival (HR:2.61, 95% CI:1.90-3.6, P<0.001).",
        "rs value":null,
        "pmid":"PubMed:10786679",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25979954",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1609T>A",
        "AA Mutation":"p.Y537N",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27551012",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1610A>C",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24055055",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1613A>G",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28283903",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1138G>C",
        "AA Mutation":"p.E380Q",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32723837",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1610A>G",
        "AA Mutation":"p.Y537C",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28283903",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1610A>C",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1613A>G",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185510",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26434753",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1610A>C",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28283903",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1607T>A",
        "AA Mutation":"p.L536H",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28283903",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537C",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26648736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26434753",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537C",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26434753",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32723837",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1609T>A",
        "AA Mutation":"p.Y537N",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"(AA)\/",
        "AA Mutation":"p.L536",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26648736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1613A>G",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24217577",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537N",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26434753",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26648736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1613A>G",
        "AA Mutation":"p.D538G",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1610A>C",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185510",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26648736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1607",
        "AA Mutation":"p.L536Q",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185510",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1609T>A",
        "AA Mutation":"p.Y537N",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:28283903",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.1610A>G",
        "AA Mutation":"p.Y537C",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:24185512",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537N",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:26648736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR1",
        "Genomic Position":"6:152011631-152424409(+) | 6q25.1-q25.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.Y537S",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:25979954",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_Loss",
        "Disease":"Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Trastuzumab",
        "Description":"PTEN loss is associated with loss of sensitivity to the HER2-antibody trastuzumab in breast cancer in smaller trials, a phase III trial (NCCTG N9831) did not show an effect of PTEN on disease-free survival.",
        "rs value":null,
        "pmid":"PubMed:24387334",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_Loss",
        "Disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Trastuzumab",
        "Description":"In a retrospective study of 111 HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapy, PTEN loss (as measured by IHC) was associated with shorter survival as measured from initiation of trastuzumab (HR = 1.92, P = 0.017) and diagnosis of first metastasis (HR = 1.69, P = 0.047).",
        "rs value":null,
        "pmid":"PubMed:21594665",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_Loss",
        "Disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Trastuzumab",
        "Description":"A subgroup of HER2-positive breast cancer patients that received first-line trastuzumab treatment were assessed for PTEN loss via IHC of FFPE samples. 46 samples showed PTEN loss while 41 did not, and PTEN loss alone was found to be significantly associated with resistance to trastuzumab (p=0.028) and shorter overall survival (p=0.008).",
        "rs value":null,
        "pmid":"PubMed:20813970",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_Expression",
        "Disease":"Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trastuzumab",
        "Description":"Trastuzumab was more effective in cell lines (SKBR3 vs. drug-resistant SKBR3\/R) and 17 patient samples that exhibit elevated PTEN expression (by IHC).",
        "rs value":null,
        "pmid":"PubMed:16404430",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04360941",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Ipatasertib + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04920708",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_Loss",
        "Disease":"Breast Cancer",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Trastuzumab",
        "Description":"In a retrospective study of 182 metastatic breast cancer patients of mixed HER2 status treated with trastuzumab-based therapy, PTEN loss (as measured by IHC) was associated with a higher risk of death measured from initiation of trastuzumab (HR = 1.64, P = 0.029) and diagnosis of first metastasis (HR = 1.85, P = 0.003).",
        "rs value":null,
        "pmid":"PubMed:21594665",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Fulvestrant + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04862663",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus + Trastuzumab + Vinorelbine",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"CYH33 + Letrozole + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04856371",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"CYH33 + Fulvestrant + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04856371",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Epirubicin hydrochloride + Lapatinib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03273595",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04216472",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Copanlisib + Eribulin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04345913",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Abemaciclib + Copanlisib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03939897",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_Loss",
        "Disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Everolimus",
        "Description":"Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger sequencing. In the BOLERO trials, patients with HER2-overexpressing advanced breast cancer were treated with trastuzumab, chemotherapy and randomized to receive either everolimus or placebo. In the pooled analysis of both trials, patients with PTEN loss (as defined by IHC staining intensity and proportion of positive tumor cells) had a longer progression-free survival with everolimus compared to placebo (HR 0.54 (95%CI 0.31 to 0.96, P=0.04) whereas patients with PTEN normal status had a hazard ration of 1.00 (95%CI 0.8 to 1.26, P=0.97). The same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combined and analyzed as hyperactive PI3K pathway. Patients with PI3K hyperactive pathway had a hazard ratio of 0.67 (95%CI 0.48 to 0.93, P=0.02) compared to HR 1.19 (95%CI 0.87 to 1.62, P=0.28) in patients with PI3K normal pathway. These trends were independently confirmed in both trials but only pooled results showed consistent statistical significance.",
        "rs value":null,
        "pmid":"PubMed:27091708",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel + Placebo",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02162719",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Placebo",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04251533",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CYH33 + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04856371",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04650581",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04305496",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PTEN",
        "Genomic Position":"10:89622870-89731687(+) | 10q23.31",
        "CDS Mutation":null,
        "AA Mutation":"PTEN_Expression",
        "Disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":4,
        "Response to Drug":"Resistance",
        "Therapies":"Everolimus,Fulvestrant",
        "Description":"Case report of a 44-year-old patient with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classical chemotherapeutic agents and anti-HER2 treatment. Thus, the combination of everolimus and fulvestrant was administered. The patient experienced stable disease and PFS of 10 months. Genetic testing of pleural effusion after disease progression revealed a PIK3CA H1047R gene mutation but was positive for PTEN expression (IHC).",
        "rs value":null,
        "pmid":"PubMed:27445490",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"NTRK3",
        "Genomic Position":"15:88420022-88799661(-) | 15q25.3",
        "CDS Mutation":null,
        "AA Mutation":"NTRK3_ETV6::NTRK3",
        "Disease":"Breast Secretory Carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Larotrectinib",
        "Description":"Shukla et al report on a remarkable case study of a 14 year old pediatric patient with refractory secretory breast carcinoma first presenting as a fibroadenoma at 8 yo. Over the next years, she experienced recurrence, multiple rounds of chemotherapy and metastasis -- until her case was presented at a virtual multidisciplinary tumor board organized by the Global Cancer Institute which recommended testing for ETV6-NTRK3 fusion. This fusion was confirmed by RNA-seq, targeted DNA and WGS sequencing as well as immunohistochemistry staining with a TRK antibody. The patient was treated with LOXO-101 (larotrectinib) in a single patient use protocol. Within two months, she experienced near complete resolution of a 10.4 \ufffd\ufffd 8.5 cm fungating chest mass with multiple satellite lesions (See Figure 2). The authors note that TERT promoter mutation and a reciprocal inversion including CDKN2A were also identified, but given what is known about LOXO-101 and ETV6-NTRK3, they  infer ETV6-NTRK3 fusion as the primary mitogenic er in this patient.",
        "rs value":null,
        "pmid":"PubMed:29623306",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03931551",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Mutation",
        "Disease":"Triple-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin,Cisplatin",
        "Description":"In an evaluation of 77 patients, those who had BRCA1\/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.022) although progression free survival and overall survival was not significantly different.",
        "rs value":null,
        "pmid":"PubMed:25847936",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Loss-of-function",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":"In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg\/day talazoparib treatment. Of patients with BRCA mutation-associated breast and ovarian cancers, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients, respectively.",
        "rs value":null,
        "pmid":"PubMed:28242752",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Loss-of-function",
        "Disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"302 patients (234 with progression events) with HER2-negative metastatic breast cancer and with a confirmed deleterious or suspected deleterious germline BRCA mutation (164 BRCA1, 129 BRCA2) had significantly improved progression-free survival and better response rate to olaparib (PARP inhibitor) than standard therapy (7.0 mo vs 4.2 mo, hazard ratio 0.58, 95% CI 0.43-0.8) in this randomized phase 3 trial (NCT02000622). For BRCA2 patients specifically, the hazard ratio was 0.68, 95% CI 0.45-0.1.07.",
        "rs value":null,
        "pmid":"PubMed:28578601",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Mutation",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation HER2\ufffd\ufffd\ufffdnegative metastatic breast cancer. 205 patients were assigned to receive olaparib and 97 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio 0.58; 95%CI 0.43 to 0.80; P<0.001). A response to treatment occurred in 100 of the 167 patients who had measurable disease in the olaparib group (59.9%; 95% CI, 52.0 to 67.4) and in 19 of the 66 patients in the standard-therapy group (28.8%; 95% CI, 18.3 to 41.3). A complete response was seen in 9.0% of the patients who had measurable disease in the olaparib group and in 1.5% in the standard-therapy ",
        "rs value":null,
        "pmid":"PubMed:28792849",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Loss-of-function",
        "Disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER\/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo.  Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86).",
        "rs value":null,
        "pmid":"PubMed:34081848",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_Loss-of-function",
        "Disease":"Triple-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":"Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1 or BRCA2. Patients were early stage but had completed chemotherapy; ER\/PR+ patients could also have concurrent hormone therapy. 82% of patients were triple negative. 72% of patients had BRCA1 germline mutations, 27% had BRCA2, and 0.4% both. 921 patients received olaparib and 915 placebo. Invasive disease-free survival (IDFS) showed improvement with olaparib treatment (86% vs 77%, HR 0.58 [0.41 to 0.82], P<0.001). For overall survival, deaths in the olaparib arm were lower (59 vs 86, HR 0.68 [0.44 to 1.05], P=0.02). The IDFS benefit was independent of whether mutation was in BRCA1 (HR=0.52, 0.39-0.70) or BRCA2 (HR 0.52, 0.30-0.86).",
        "rs value":null,
        "pmid":"PubMed:34081848",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00679783",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03025035",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Paclitaxel + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01149083",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Rucaparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00664781",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02034916",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRCA2",
        "Genomic Position":"13:32889617-32973805(+) | 13q13.1",
        "CDS Mutation":null,
        "AA Mutation":"BRCA2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR2",
        "Genomic Position":"10:123239371-123357917(-) | 10q26.13",
        "CDS Mutation":"c.1650T>A",
        "AA Mutation":"p.N550K",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30914635",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR2",
        "Genomic Position":"10:123239371-123357917(-) | 10q26.13",
        "CDS Mutation":"c.1187T>A",
        "AA Mutation":"p.V396D",
        "Disease":"carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:30914635",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR2",
        "Genomic Position":"10:123239371-123357917(-) | 10q26.13",
        "CDS Mutation":"c.1614G>A",
        "AA Mutation":"p.M538I",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32723837",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR2",
        "Genomic Position":"10:123239371-123357917(-) | 10q26.13",
        "CDS Mutation":"c.1650T>A",
        "AA Mutation":"p.N550K",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Endocrine therapy",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32723837",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MMP2",
        "Genomic Position":"16:55512883-55540603(+) | 16q12.2",
        "CDS Mutation":null,
        "AA Mutation":"MMP2_SERUM_LEVELS",
        "Disease":"Inflammatory Breast Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab",
        "Description":"MMP2 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. High bMMP2 was correlated with better disease-free survival (DFS, p=0.001) and overall survival (OS, p=0.032). Correlation to DFS was also found after multivariate analysis (p=0.003, Hazard Ratio [HR]: 0.115). bMMP2 was associated with relapse (p=0.002) and death (p=0.049). During treatment, significant increase in MMP2 was observed in 100% of patients.",
        "rs value":null,
        "pmid":"PubMed:26921265",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"TOP2A",
        "Genomic Position":"17:38544768-38574202(-) | 17q21.2",
        "CDS Mutation":null,
        "AA Mutation":"TOP2A_EXPRESSION",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin",
        "Description":"In a retrospective study, TOP2A expression was assessed by IHC for 108 breast cancer patients (from TAX 303 trial). TOP2A expression was associated with a higher probability of response in doxorubicin treated but not in docetaxel treated breast cancer patients.",
        "rs value":null,
        "pmid":"PubMed:15486187",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CDK6",
        "Genomic Position":"7:92234235-92463231(-) | 7q21.2",
        "CDS Mutation":null,
        "AA Mutation":"CDK6_Overexpression",
        "Disease":"Estrogen-receptor Positive Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fulvestrant",
        "Description":"In two cohorts (n=45 and n=46) of ER+ breast cancer patients who had received fulvestrant, CDK6 overexpression correlated with shorter median time to progression in both cohorts (2.5 vs. 8.2 months and 3.4 vs. 8.9 months for CDK6 overexpression vs. normal expression). CDK6 expression did not correlate with other lines of treatment (N=68, tamoxifen or endocrine therapy). Four fulvestrant-resistant cell lines were derived from estrogen responsive and fulvestrant sensitive parental breast cancer cell line MCF-7\/SO.5. Gene expression profiling showed upregulation of CDK6 in the fulvestrant resistant derivatives. Knockdown of CDK6 in these derivative cells resulted in fulvestrant sensitivity.",
        "rs value":null,
        "pmid":"PubMed:27252418",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Ipatasertib + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04920708",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Fulvestrant + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04862663",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01226316",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BAY1125976",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01915576",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01226316",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02162719",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02299999",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cyclophosphamide + Doxorubicin hydrochloride + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05498896",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel + Placebo",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04305496",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fulvestrant + Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04650581",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_ATM_unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_undefined_or_FANCD2_undefined_or_FANCE_undefined_or_FANCF_undefined_or_FANCG_undefined_or_FANCL_undefined_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04768426",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"MK2206",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01277757",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT03337724",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Placebo",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT03337724",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AKT1",
        "Genomic Position":"14:105235686-105260461(-) | 14q32.33",
        "CDS Mutation":null,
        "AA Mutation":"AKT1_E17K",
        "Disease":"Breast Cancer",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capivasertib",
        "Description":"In a phase-I study of AZD5363, partial response was observed in 2 patients with breast and ovarian carcinoma, respectively, and AKT1 E17K mutations. While full study results have not yet been published, this paper highlights in vitro results that further confirm the role of AKT E17K mutation.",
        "rs value":null,
        "pmid":"PubMed:26351323",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"MMP9",
        "Genomic Position":"20:44637547-44645200(+) | 20q13.12",
        "CDS Mutation":null,
        "AA Mutation":"MMP9_SERUM_LEVELS",
        "Disease":"Inflammatory Breast Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Bevacizumab",
        "Description":"MMP9 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. Low bMMP9 was correlated with better OS (p=0.022) and non-significantly associated with longer DFS (p=0.071). Correlation to DFS was also found after multivariate analysis (p=0.041, HR: 3.511). bMMP9 was associated with death (p=0.035). During treatment, a significant decrease in MMP9 levels (p<0.001) was observed in 87% of patients.",
        "rs value":null,
        "pmid":"PubMed:26921265",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"RSF1",
        "Genomic Position":"11:77371041-77532063(-) | 11q14.1",
        "CDS Mutation":null,
        "AA Mutation":"RSF1_Amplification",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tamoxifen",
        "Description":"In retrospective study, 413 patients were assessed for RSF1 amplification. 28 patients with RSF1 amplification did not show a benefit from adjuvant tamoxifen compared to placebo (12 treated vs 16 placebo). 381 patients without amplification did show a benefit compared to placebo (187 treated vs 194 placebo).",
        "rs value":null,
        "pmid":"PubMed:24367492",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"AGR2",
        "Genomic Position":"7:16831435-16844704(-) | 7p21.1",
        "CDS Mutation":null,
        "AA Mutation":"AGR2_EXPRESSION",
        "Disease":"Breast Cancer",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Tamoxifen",
        "Description":"mRNA expression of AGR2 in 61 patients with tamoxifen treated postmenopausal breast cancer was determined by qRT-PCR and was inversely associated with treatment response and progression free survival (p= 0.0011, p = 0.0366 respectively). AGR2 protein expression as assessed by IHC was not significantly associated with treatment outcome.",
        "rs value":null,
        "pmid":"PubMed:24167368",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK4_unspecified_and_ESR1_unspecified",
        "Disease":"breast | carcinoma | ER-positive carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erdafitinib + Fulvestrant + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03238196",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK4",
        "Genomic Position":"12:58141510-58146304(-) | 12q14.1",
        "CDS Mutation":null,
        "AA Mutation":"CDK6_unspecified_and_ESR1_unspecified",
        "Disease":"breast | carcinoma | ER-positive carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Erdafitinib + Fulvestrant + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03238196",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BARD1",
        "Genomic Position":"2:215590370-215674428(-) | 2q35",
        "CDS Mutation":null,
        "AA Mutation":"BARD1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bicalutamide + Ribociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03090165",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bicalutamide + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02605486",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | HER-positive carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enzalutamide + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02091960",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04360941",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | HER-positive carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enzalutamide + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02099864",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bicalutamide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02299999",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"EP0062",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05573126",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"SHR2554 + SHR3680",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04355858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Orteronel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01990209",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Prasterone",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02000375",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enzalutamide",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02676986",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enzalutamide + Taselisib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02457910",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Cyclophosphamide + Epirubicin + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05582499",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Proxalutamide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT04103853",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Cyclophosphamide + Epirubicin + Nab-paclitaxel + Pyrotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05582499",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dexamethasone + Docetaxel + Seviteronel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04947189",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enobosarm + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02971761",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enobosarm",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02368691",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Seviteronel",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02580448",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Epirubicin + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04213898",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ESR1_unspecified",
        "Disease":"breast | carcinoma | ER-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enobosarm",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04869943",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Diindolylmethane",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01612910",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Transdermal 4-hydroxytestosterone",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02067741",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Prasterone",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00972023",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bicalutamide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02353988",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bicalutamide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02348281",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enzalutamide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02750358",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bicalutamide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03055312",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | HER-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Orteronel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01990209",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Seviteronel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02130700",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ESR1_unspecified",
        "Disease":"breast | carcinoma | ER-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"EG017",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05673694",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ESR1_unspecified",
        "Disease":"breast | carcinoma | ER-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enzalutamide + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02955394",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ESR1_unspecified",
        "Disease":"breast | carcinoma | ER-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Aromatase inhibitors + Bicalutamide",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02910050",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ESR1_unspecified",
        "Disease":"breast | carcinoma | ER-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enobosarm",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01616758",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ESR1_unspecified",
        "Disease":"breast | carcinoma | ER-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Enobosarm",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02463032",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04443348",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_and_ESR1_unspecified",
        "Disease":"breast | carcinoma | ER-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Transdermal 4-hydroxytestosterone",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02067741",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AR",
        "Genomic Position":"X:66764465-66950461(+) | Xq12",
        "CDS Mutation":null,
        "AA Mutation":"AR_unspecified_or_PTEN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Alpelisib + Enzalutamide",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03207529",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CYP2D6",
        "Genomic Position":"22:42522501-42526908(-) | 22q13.2",
        "CDS Mutation":null,
        "AA Mutation":"CYP2D6_unspecified",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tamoxifen citrate",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01124695",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lapatinib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00111787",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lapatinib + Paclitaxel + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01688609",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02226757",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02299999",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Doxorubicin-loaded anti-EGFR immunoliposomes",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02833766",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sapitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02299999",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD4547",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02299999",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Gemcitabine + Panitumumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00894504",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Pyrotinib",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Poziotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02544997",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Canertinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00051051",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Pyrotinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03080805",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Gefitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01732276",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified_or_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Neratinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00146172",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_ATR_unspecified_or_BAP1_unspecified_or_BARD1_unspecified_or_BLM_unspecified_or_BRIP1_unspecified_or_CHEK1_unspecified_or_CDK12_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_MRE11_unspecified_or_NBN_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_WRN_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"HX008 + Niraparib + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04508803",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"BAY1895344 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04095273",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_or_MRE11A_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03344965",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCG_unspecified_or_FANCL_unspecified_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_RAD51D_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02401347",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ATM",
        "Genomic Position":"11:108093559-108239826(+) | 11q22.3",
        "CDS Mutation":null,
        "AA Mutation":"ATM_unspecified_or_BARD1_unspecified_or_CHEK2_unspecified_or_FANCC_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_SLX4_unspecified_or_XRCC2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05033756",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CHEK2",
        "Genomic Position":"22:29083751-29137826(-) | 22q12.1",
        "CDS Mutation":null,
        "AA Mutation":"CHEK2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CHEK2",
        "Genomic Position":"22:29083751-29137826(-) | 22q12.1",
        "CDS Mutation":null,
        "AA Mutation":"CHEK2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"VEGFA",
        "Genomic Position":"6:43738444-43752346(+) | 6p21.1",
        "CDS Mutation":null,
        "AA Mutation":"VEGFA_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02299999",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR2",
        "Genomic Position":"14:64699806-64761078(-) | 14q23.2-q23.3",
        "CDS Mutation":null,
        "AA Mutation":"ESR2_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Estradiol",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03941730",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR2",
        "Genomic Position":"14:64699806-64761078(-) | 14q23.2-q23.3",
        "CDS Mutation":null,
        "AA Mutation":"ESR2_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Estradiol",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01083641",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ESR2",
        "Genomic Position":"14:64699806-64761078(-) | 14q23.2-q23.3",
        "CDS Mutation":null,
        "AA Mutation":"ESR2_unspecified_and_(ERBB2_absent_and_ESR1_absent_and_PGR_absent)",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tamoxifen",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02062489",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PPP2R2A",
        "Genomic Position":"8:26150732-26228402(+) | 8p21.2",
        "CDS Mutation":null,
        "AA Mutation":"PPP2R2A_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Patritumab deruxtecan",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04610528",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Patritumab deruxtecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02980341",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Patritumab deruxtecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04965766",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CCR5",
        "Genomic Position":"3:46411633-46417673(+) | 3p21.31",
        "CDS Mutation":null,
        "AA Mutation":"CCR5_unspecified_and_CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Leronlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03838367",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CHEK1",
        "Genomic Position":"11:125496236-125527031(+) | 11q24.2",
        "CDS Mutation":null,
        "AA Mutation":"CHEK1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR3",
        "Genomic Position":"4:1795039-1810599(+) | 4p16.3",
        "CDS Mutation":null,
        "AA Mutation":"FGFR3_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dovitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:nan",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TACSTD2",
        "Genomic Position":"1:59041099-59043166(-) | 1p32.1",
        "CDS Mutation":null,
        "AA Mutation":"TACSTD2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05332561",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MAP2K1",
        "Genomic Position":"15:66679155-66784650(+) | 15q22.31",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.L115P",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"PD0325901",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:22402123",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CDK12",
        "Genomic Position":"17:37618292-37691399(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"CDK12_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD54L",
        "Genomic Position":"1:46713404-46744144(+) | 1p34.1",
        "CDS Mutation":null,
        "AA Mutation":"RAD54L_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":null,
        "AA Mutation":"ALK_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02034981",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BCL2",
        "Genomic Position":"18:60790579-60987361(-) | 18q21.33",
        "CDS Mutation":null,
        "AA Mutation":"BCL2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Letrozole + Palbociclib + Venetoclax",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03900884",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB4_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03125928",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Trastuzumab + Tucatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04789096",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cyclophosphamide + Paclitaxel + Pertuzumab + Trastuzumab + Trastuzumab-emtansine + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03726879",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Pertuzumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03820141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Cyclophosphamide + Docetaxel or Paclitaxel + Epirubicin hydrochloride + Pertuzumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03894007",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Trastuzumab-emtansine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04740918",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Trastuzumab + Vinorelbine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04759248",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Pembrolizumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03095352",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sintilimab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05429684",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04360941",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Trastuzumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02129556",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tesetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03952325",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02838823",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04251169",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PGG beta-glucan + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05159778",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04448886",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Doxorubicin hydrochloride liposome + Ipilimumab + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03409198",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Exemestane + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02997995",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Tesetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03952325",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Decitabine + Doxorubicin hydrochloride + Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02957968",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab + Tesetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03952325",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03841747",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05093387",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04243616",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03095352",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04895358",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Tesetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03952325",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cyclophosphamide + Doxorubicin hydrochloride + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03800836",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cyclophosphamide + Doxorubicin hydrochloride liposome",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03164993",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Eribulin + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02513472",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Ipatasertib + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03800836",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Ruxolitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03012230",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03800836",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Ipatasertib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03800836",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02555657",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02447003",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Radiotherapy + Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04690855",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Gemcitabine + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02755272",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Cyclophosphamide + Epirubicin hydrochloride + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04770272",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Carboplatin + Nab-paclitaxel + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04722718",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pelareorep + Retifanlimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04445844",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03036488",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cemiplimab + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04243616",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03095352",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02819518",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05382286",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Carboplatin + Docetaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05475678",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02685059",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab + Carboplatin + Gemcitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04739670",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Cyclophosphamide + Doxorubicin hydrochloride + Paclitaxel + Pembrolizumab + Trilaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05112536",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Cyclophosphamide + Decitabine + Doxorubicin hydrochloride + Paclitaxel + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02957968",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Durvalumab + Oleclumab + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03616886",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Nab-paclitaxel + Tocilizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03424005",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"PGG beta-glucan + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT02981303",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Radiotherapy + Sintilimab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03812549",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nab-paclitaxel + SG001",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05068141",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02530489",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Eribulin + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04913571",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cisplatin + Nab-paclitaxel + Olaparib + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05174832",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Carboplatin + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05266937",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02299999",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Anlotinib + Anthracycline + Nab-paclitaxel + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04914390",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Sacituzumab govitecan",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03424005",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02411656",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Avelumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02926196",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03281954",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Chemotherapy + PVX-410 + Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04634747",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02628132",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Olaparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02484404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Ipatasertib + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04177108",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nab-paclitaxel + Pembrolizumab + Radiotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05233696",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Cyclophosphamide + Doxorubicin hydrochloride + Filgrastim or Pegfilgrastim + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03197935",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Gemcitabine + Trilaciclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04799249",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Capecitabine + Carboplatin + Gemcitabine",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03371017",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nab-paclitaxel + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04085276",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335006",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335006",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04148911",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Nab-paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02425891",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01848834",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified_and_ERBB4_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Nab-paclitaxel + Pyrotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04872985",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NF1",
        "Genomic Position":"17:29421945-29704695(+) | 17q11.2",
        "CDS Mutation":null,
        "AA Mutation":"NF1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"TAS0612",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04586270",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NF1",
        "Genomic Position":"17:29421945-29704695(+) | 17q11.2",
        "CDS Mutation":null,
        "AA Mutation":"NF1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Famitinib + SHR7390",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04355858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51B",
        "Genomic Position":"14:68286525-69062713(+) | 14q24.1",
        "CDS Mutation":null,
        "AA Mutation":"RAD51B_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FANCL",
        "Genomic Position":"2:58386382-58468485(-) | 2p16.1",
        "CDS Mutation":null,
        "AA Mutation":"FANCL_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MTOR",
        "Genomic Position":"1:11166592-11322564(-) | 1p36.22",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.F2108L",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Rapamycin",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:27279227",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RET",
        "Genomic Position":"10:43572475-43625799(+) | 10q11.21",
        "CDS Mutation":null,
        "AA Mutation":"RET_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vandetanib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01934335",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Cyclophosphamide + Paclitaxel + WT1, Cyclin B1, CEF antigen-loaded autologous DC vaccine + doxorubicin hydrochloride",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02018458",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cyclophosphamide + Docetaxel + Doxorubicin hydrochloride + Epirubicin hydrochloride + Fluorouracil + GSK2302024A + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01220128",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"WT1",
        "Genomic Position":"11:32409321-32457176(-) | 11p13",
        "CDS Mutation":null,
        "AA Mutation":"WT1_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Galinpepimut-S + Pembrolizumab + Sargramostim",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03761914",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | juvenile xanthogranuloma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Vemurafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01524978",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | juvenile xanthogranuloma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dabrafenib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03794297",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | juvenile xanthogranuloma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"HLX208",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05092815",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRAF",
        "Genomic Position":"7:140434279-140624564(-) | 7q34",
        "CDS Mutation":null,
        "AA Mutation":"BRAF_V600",
        "Disease":"haematopoietic and lymphoid tissue | lymphoid neoplasm | juvenile xanthogranuloma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Dabrafenib + Trametinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02281760",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51D",
        "Genomic Position":"17:33427691-33446832(-) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"RAD51D_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51D",
        "Genomic Position":"17:33427691-33446832(-) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"RAD51D_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PDGFRB",
        "Genomic Position":"5:149493400-149535423(-) | 5q32",
        "CDS Mutation":null,
        "AA Mutation":"PDGFRB_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Famitinb",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04355858",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NT5E",
        "Genomic Position":"6:86159809-86205496(+) | 6q14.3",
        "CDS Mutation":null,
        "AA Mutation":"NT5E_unspecified_and_ERBB2_absent_and_ESR1_absent_and_PGR_absent",
        "Disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Carboplatin + Durvalumab + Oleclumab + Paclitaxel",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03616886",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"CYH33 + Letrozole + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04856371",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"CYH33 + Fulvestrant + Palbociclib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04856371",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Paclitaxel + Pelareorep",
        "Description":null,
        "rs value":null,
        "pmid":"Corporate website:NCT01656538",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified_and_(ESR1_unspecified_or_PGR_unspecified_or_(ESR1_unspecified_and_PGR_unspecified))",
        "Disease":"breast | carcinoma | hormone receptor-positive carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"CYH33 + Fulvestrant",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04856371",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51C",
        "Genomic Position":"17:56769934-56811703(+) | 17q22",
        "CDS Mutation":null,
        "AA Mutation":"RAD51C_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"RAD51C",
        "Genomic Position":"17:56769934-56811703(+) | 17q22",
        "CDS Mutation":null,
        "AA Mutation":"RAD51C_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"BRIP1",
        "Genomic Position":"17:59758627-59940882(-) | 17q23.2",
        "CDS Mutation":null,
        "AA Mutation":"BRIP1_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Niraparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05232006",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Talazoparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04756765",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"PALB2",
        "Genomic Position":"16:23614491-23652631(-) | 16p12.2",
        "CDS Mutation":null,
        "AA Mutation":"PALB2_unspecified",
        "Disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capecitabine + Platinum-based chemotherapy",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":"c.3736G>A",
        "AA Mutation":"p.D1246N",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Crizotinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:32234363",
        "source_db":"COSMIC"
    }
]